Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas

Cancer Treat Res. 2004;120:129-50. doi: 10.1007/1-4020-7856-0_8.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Gastrointestinal Neoplasms / drug therapy*
  • Gastrointestinal Neoplasms / enzymology
  • Humans
  • Imatinib Mesylate
  • Mutation / genetics*
  • Piperazines / therapeutic use*
  • Platelet-Derived Growth Factor / genetics
  • Platelet-Derived Growth Factor / metabolism
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Protein-Tyrosine Kinases / genetics*
  • Proto-Oncogene Proteins c-kit / genetics
  • Proto-Oncogene Proteins c-kit / metabolism
  • Pyrimidines / therapeutic use*
  • Receptors, Platelet-Derived Growth Factor / genetics
  • Receptors, Platelet-Derived Growth Factor / metabolism
  • Sarcoma / drug therapy*
  • Sarcoma / enzymology
  • Soft Tissue Neoplasms / drug therapy*
  • Soft Tissue Neoplasms / enzymology

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Platelet-Derived Growth Factor
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins c-kit
  • Receptors, Platelet-Derived Growth Factor